*Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
PAVmed Announces Reverse Stock Split PR Newswire
Market data is delayed by at least 15 minutes.
    Latest Story Top Stories on PAVM
    Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025
    8:01a ET October 29 '25 PR Newswire

    Conference Call and Webcast at 8:30 AM Eastern Time

    Lucid Diagnostics Inc.(Nasdaq: LUCD)("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, November 12, 2025, at 8:30 AM ET. During the call,Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition,Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's third quarter 2025 financial results.

    https://mma.prnewswire.com/media/2003008/Lucid_TM_Logo.jpg

    Thewebcastwill be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.

    Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.

    About Lucid Diagnostics

    Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard(R) Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck(R) Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

    For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

    https://edge.prnewswire.com/c/img/favicon.png?sn=NY09116&sd=2025-10-29

    View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-november-12-2025-302597099.html

    SOURCE Lucid Diagnostics

    https://rt.newswire.ca/rt.gif?NewsItemId=NY09116&Transmission_Id=202510290801PR_NEWS_USPR_____NY09116&DateId=20251029

    COMTEX_469885910/1005/2025-10-29T08:01:59

    Lucid Diagnostics Announces Positive Data from the Largest Reported R...
    8:02a ET December 9 '25 PR Newswire
    Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Rank...
    8:15a ET November 20 '25 PR Newswire
    Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Di...
    8:15a ET November 13 '25 PR Newswire
    PAVmed Provides Business Update and Reports Third Quarter 2025 Financ...
    8:02a ET November 13 '25 PR Newswire
    Lucid Diagnostics Provides Business Update and Reports Third Quarter ...
    8:01a ET November 12 '25 PR Newswire
    PAVmed to Hold a Business Update Conference Call and Webcast on Novem...
    8:01a ET October 30 '25 PR Newswire
    Lucid Diagnostics to Hold a Business Update Conference Call and Webca...
    8:01a ET October 29 '25 PR Newswire
    Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit
    8:03a ET October 15 '25 PR Newswire

    Market data provided by News provided by